Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Perrigo (NY: PRGO )

27.12 -0.36 (-1.31%)
Streaming Delayed Price Updated: 10:34 AM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Perrigo

< Previous 1 2 3 4 Next >
With a Big Catalyst in Hand, Is Perrigo Company a Buy?
Regulators just ruled that one of its products can be sold over the counter. 
Via The Motley Fool
PRGO Stock Alert: Perrigo Climbs on Landmark FDA Birth Control Decision
Perrigo (PRGO) stock is rising on Friday as investors react to the company's over-the-counter birth control pill getting FDA approval. 
Via InvestorPlace
FDA Approves Over-the-Counter Birth Control Pill. Is the Pill Maker's Stock Set to Soar?
Perrigo picked up a milestone regulatory win. 
Via The Motley Fool
First Birth Control Pill For OTC Use In US Lands FDA Approval
Perrigo Company plc (NYSE: PRGO) shares are trading higher after the FDA approved the company's Opill, a progestin-only daily oral contraceptive for over-the-counter  
Via Benzinga
Perrigo Picks Former Bayer Executive As New CEO
Perrigo Co PLC (NYSE: PRGO) disclosed the appointment of Patrick Lockwood-Taylor as its new President, CEO and member of the Board of Directors, 
Via Benzinga
$4.5M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed mostly higher on Thursday, there were a few notable insider trades. 
Via Benzinga
Perrigo Q1 Earnings Beat Estimates On Strategic Pricing, CEO Plans Retirement
Via Benzinga
FDA Sets New Adcomm Date To Review Perrigo's Oral Contraceptive Pill For OTC Use
Via Benzinga
Earnings Outlook For Perrigo Co
Via Benzinga
Why Perrigo Stock Tanked on Tuesday
A double miss and a guidance cut badly affected investor sentiment. 
Via The Motley Fool
FDA Raises Concerns Regarding Perrigo's OTC Birth Control Pill, Casts Doubts Over Real-World Use
The FDA's Nonprescription Drugs Advisory Committee (NDAC) and the Obstetrics, Reproductive, and Urologic Drugs Advisory Committee (ORUDAC) will be meeting this week to review Perrigo Company... 
Via Benzinga
Republicans Seek Documents, Schedule Hearing Related To FDA's Response To Baby-Formula Shortage
House Republicans are reportedly speeding up their scrutiny of the FDA and the White House's handling of the baby formula shortage last year. 
Via Benzinga
Insiders Selling Perrigo And 3 Other Stocks
The Nasdaq Composite dropped by around 2% on Thursday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023
Via Benzinga
FDA Postpones Review Meeting For First OTC Contraceptive Option From Perrigo
Via Benzinga
Earnings Scheduled For February 27, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million. 
Via Benzinga
7 Perfect Presents to Gift Your 2023 Stock Portfolio
As we leave 2022 behind, these hot stocks to buy have significant potential and serious catalysts as we move into New Year 2023. 
Via InvestorPlace
SWEDEN’S SKINCARE SENSATION ACO EXTENDS PRESENCE INTO US TIMED TO THE HOLIDAY SEASON
Stolkholm’s Best Kept Skincare Secret Is The Perfect Gift For Giving 
From ACO
Via GlobeNewswire
Perrigo, Tripadvisor, Lyft, And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining more than 400 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday. 
Via Benzinga
Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday's Mid-Day Session
Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 39.4% to $1.4529 after the company announced a payment assignment from the Centers for Medicare & Medicaid Services for the ProSense breast... 
Via Benzinga
Perrigo Shares Fall As Investors React To Lowered FY22 Profit Guidance
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2022
Upgrades For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral to Buy. The current stock performance of Iris Energy shows a 52-week-high of $17.97 and a 52-week-low... 
Via Benzinga
FDA Schedules AdComm Review For First Over The Counter Birth Control Pill
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2022
Upgrades 
Via Benzinga
Is Sanofi A Buy, Despite Recent Stumbles?
Pharmaceuticals are subject to whiplash trade. That's evident with sharp moves lower in Sanofi, GSK and Teva on news about clinical trials and legal actions. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter. 
Via Benzinga
Perrigo Stock Mystery; Big Money Loves It, Though Profits Slim
Institutional investors like mutual funds can't get enough of Perrigo stock. It has an A Accumulation/Distribution Rating. 
Via Investor's Business Daily
Perrigo Seeks FDA Approval For the First OTC Contraceptive Pill
Perrigo Company plc's (NYSE: PRGO) HRA Pharma has 
Via Benzinga
The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.